Our Initiative and Impact

Covid 19 vaccinations- study of impact on human bodies:-

Almost all countries across the globe have introduced vaccine programs for its people in an effort to end the ongoing and painful COVID-19 pandemic. To curb the spread of the virus and to reduce the intensity, it is much required for a vast majority of people to be completely vaccinated. There are 11 vaccines at the moment which are authorized/approved for use in multiple countries worldwide. According to clinical trial data, these vaccines have demonstrated relatively high efficacy with a large sample size in preventing COVID- infection. However, response to these vaccines vary at an individual level and can be influenced by a multitude of biological factors, including the function of the microbiome.

A paper from Pharma Intelligence states that the microbiome plays a significant role in immunity, and may be an underlying factor explaining why elderly people and those with certain comorbidities are at higher risk of infection. The underlying impact of microbiome dysbiosis on immunity may not only increase instances of severe disease in high-risk groups but may also affect their response to the COVID-19 vaccines. Therefore, it is vital to understand the role of the microbiome in immunity and vaccine response, and how it may impact the effectiveness of vaccine programs in the real world.

Kenya has seen two vaccines namely AstraZeneca, from Serum Institute of India and Sputnik, from the Gamaleya Research Institute. Whilst Sputnik was imported by Dinlas Pharmaceuticals, it was re-exported due to administrative issues.

Dinlas Pharmaceuticals had prepared themselves for the vaccination drive by having strategies in place for fair distribution and assistance in administration of the Sputnik vaccine. Nurses and healthcare staff across the partner companies of Mr. Jayesh Saini, Kenya; like Bliss Healthcare, Nairobi West Hospital, Clinix Healthcare etc. were specifically trained to administer the jabs manage mass volume of patients. This was done and signed off by Ministry of Health (MOH) / Afya house medical team. Mr. Jayesh Saini touched upon his vision behind establishing the state-of-the-art RnD department at Dinlas Pharmaceuticals LTD recently. In addition to having top notch manufacturing and packaging machines - it’s equally important to have the above to encourage the team to continue the trials for new molecules 24/7. This remains paramount for the continuously evolving journey of a well-established pharmaceutical setup.

Studies so far says, a majority of the risk factors for severe COVID-19 are associated with altered microbiota composition. The underlying impact of microbiome dysbiosis on immunity may not only increase risk of disease in people in these risk groups but may also affect their response to the COVID-19 vaccines. Elderly people in care homes have been hit particularly hard by the pandemic, and the vaccine is vital to prevent further outbreaks in such facilities. Immunosenescence is a feature of aging and frailty, which may blunt responsiveness to vaccines and could be driven by dysbiosis. Also, given the large prevalence of high-risk comorbidities in the general population which feature impaired immunity through dysbiosis, there is a risk that a vaccine may not actually be as effective in the real-world setting as it has been shown to be in trials. Moreover, researchers have suggested that vaccine adverse effects observed in high-risk patients, such as the 23 elderly people who died after receiving an mRNA-based vaccine in Sweden, may have been influenced by dysbiosis.

It is imperative that further research must be conducted to assess vaccine effectiveness in high-risk individuals and better understand the role of the microbiome in influencing response. San Diego, US-based Persephone Biosciences this year initiated the VOICES (Vaccine Observation to Include all Communities for Equitable Science) study in order to find an answer to this important research question, and it is anticipated to complete in late 2022 according to Trialtrove. High-risk individuals may benefit from microbiome-modulating therapies to boost their immunity and improve their response to vaccines. If vaccine responsiveness is high for all individuals in a population, herd immunity may be achieved more effectively, and focusing on improving microbiome health may be the key to reaching this goal.

Water Management:-

As a common good, water is a shared natural resource and we believe that the smallest of efforts add up to make a huge difference. At DinlasPharma our intention is to improve water management by focusing on optimization, reuse and recycle of this resource.
Believing in the principle of 3R’s, we have made efforts to reduce our water consumption by adopting best practices, alternatively reusing and recycling the treated wastewater in cooling towers, boilers and landscaping.

Waste water Management:-

We understand that ‘wastewater is a resource’ that can be adequately treated to successfully satisfy most water demands, simultaneously achieving pollution prevention and reduction in wastewater discharges. We have Effluent treatment plant which will take care of process water and discharge chemical free water to the Municipal sewer lines. Hence preserving the environment.

Solar Energy:-

We as a responsible business entity, we try our best to use solar energy whenever possible as part of environmental energy policy.